查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593861

肝癌治疗药物市场：按类型、分销管道划分 - 全球预测 2025-2030

Liver Cancer Drugs Market by Type (Immuno Therapy, Targeted Therapy), Distribution channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肝癌治疗市场价值为8.667亿美元，预计到2024年将达到9.876亿美元，复合年增长率为14.04%，到2030年将达到21.7453亿美元。

肝癌药物研究的范围包括用于治疗、预防和管理肝癌的药物，包括化疗、免疫治疗、标靶治疗和最近核准的基因治疗。这个不断扩大的市场是由肝癌发病率的增加、医疗技术的进步和人们的认识不断提高所推动的。由于肝癌仍然是全球癌症死亡的主要原因之一，因此迫切需要有效的治疗。最终用途涵盖医院、门诊手术中心和肿瘤诊所，主要涉及医疗保健提供者和患者。市场开拓是由对研发的大力投资、新治疗方法的核准以及与大型製药公司、生物技术公司和学术机构的合作所推动的。个人化医疗、伴同性诊断和射频消融等非侵入性治疗方法的发展存在机会。渴望扩张的公司应寻求 FDA 和 EMA核准途径，以快速推出创新药物。虽然机会存在，但挑战包括高昂的研究成本、严格的监管要求以及与新药相关的潜在副作用。市场限制是由于罕见肝癌亚型的竞争格局和患者人数有限，需要以患者为中心的方法和具有成本效益的治疗方法来扩大采用。分子分析和生物标记发现可以作为创新的目标，以提高治疗效果和患者结果。联合治疗的探索和现有治疗方法的最佳化也是潜在的成长途径。肝癌药物市场是一个动态市场，其特征是发展迅速、竞争激烈，需要采取适应性策略来维持业务成长。透过专注于标靶药物输送系统并利用人工智慧在药物开发中进行预测分析，我们可以进一步挖掘市场潜力，并使相关人员能够有效地利用机会和限制。

主要市场统计
基准年[2023] 8.667 亿美元
预测年份 [2024] 9.876 亿美元
预测年份 [2030] 217,453 万美元
复合年增长率（%） 14.04%

市场动态：揭示快速发展的肝癌药物市场的关键市场洞察

肝癌药物市场正因供需的动态互动而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 肝癌盛行率上升
    • 提高对肝癌的认识
    • 精准医学的快速引入和标靶治疗的出现
  • 市场限制因素
    • 开发成本高
  • 市场机会
    • 肝癌药物继续核准监管机构批准
    • 扩大开发新药研发投入
  • 市场挑战
    • 肝癌治疗药物的副作用

波特五力：驾驭肝癌药物市场的策略工具

波特的五力框架是了解肝癌药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肝癌治疗药物市场的外部影响

外部宏观环境因素对肝癌治疗药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肝癌治疗药物市场的竞争状况

肝癌治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵肝癌治疗市场供应商绩效评估

FPNV定位矩阵是评估肝癌治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘肝癌治疗市场的成功之路

肝癌治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肝癌发生率增加
      • 加强对肝癌的认识活动
      • 精准医学的快速引入和标靶治疗的出现
    • 抑制因素
      • 肝癌药物研发成本高
    • 机会
      • 肝癌治疗的监管核准正在进行中
      • 加大开发新药研发投入
    • 任务
      • 肝癌治疗药物的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肝癌治疗药物市场：依类型

  • 免疫疗法
  • 标靶治疗

第七章肝癌治疗药物市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第八章 北美和南美肝癌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区肝癌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲肝癌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celsion Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Lion TCR Pte. Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Sanofi SA
Product Code: MRR-434CCDA05287

The Liver Cancer Drugs Market was valued at USD 866.70 million in 2023, expected to reach USD 987.60 million in 2024, and is projected to grow at a CAGR of 14.04%, to USD 2,174.53 million by 2030.

The scope of research on liver cancer drugs encompasses pharmaceuticals used for treatment, prevention, and management of liver cancer, including chemotherapy, immunotherapy, targeted therapy, and recently approved gene therapy options. This expanding market sees rising demand driven by increasing liver cancer incidence, advancements in medical technology, and growing awareness. The necessity lies in the urgent need for effective treatments as liver cancer remains one of the leading causes of cancer mortality globally. Applications span hospitals, ambulatory surgical centers, and oncology clinics, with end-use sectors primarily involving healthcare providers and patients. Market growth is influenced by robust investment in research and development, approval of novel therapies, and collaborations between pharmaceutical giants, biotechnology firms, and academic institutions. Opportunities arise in the development of personalized medicine, companion diagnostics, and non-invasive treatment options like radiofrequency ablation. Companies keen on expansion should focus on the FDA and EMA approval pathways to swiftly introduce innovative drugs. Despite opportunities, challenges include high research costs, stringent regulatory requirements, and potential side effects associated with new drugs. Market limitations are driven by the competitive landscape and the limited patient population for rare liver cancer subtypes, necessitating patient-centric approaches and cost-effective therapies to increase adoption. Innovations can target molecular profiling and biomarker discovery to improve treatment efficacy and patient outcomes. Researching combination therapies and optimizing existing treatments also offers potential growth pathways. The liver cancer drug market remains dynamic, characterized by rapid advancements and strong competition, demanding adaptive strategies to sustain business growth. Emphasizing targeted drug delivery systems and harnessing AI for predictive analytics in drug development could further leverage market potential, ensuring stakeholders navigate both opportunities and constraints effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 866.70 million
Estimated Year [2024] USD 987.60 million
Forecast Year [2030] USD 2,174.53 million
CAGR (%) 14.04%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liver Cancer Drugs Market

The Liver Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of liver cancer
    • Increasing initiatives for the awareness regarding liver cancer
    • Rapid adoption of precision medicine and emergence of targeted therapies
  • Market Restraints
    • High cost for developing liver cancer drugs
  • Market Opportunities
    • Ongoing regulatory approvals for the liver cancer drugs
    • Growing R&D investments for the development of novel drugs
  • Market Challenges
    • Adverse side effects of liver cancer drugs

Porter's Five Forces: A Strategic Tool for Navigating the Liver Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liver Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liver Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liver Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liver Cancer Drugs Market

A detailed market share analysis in the Liver Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liver Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liver Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liver Cancer Drugs Market

A strategic analysis of the Liver Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liver Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Celsion Corporation, Eisai Co., Ltd., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd, Lion TCR Pte. Ltd., Merck & Co., Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Liver Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Immuno Therapy and Targeted Therapy.
  • Based on Distribution channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of liver cancer
      • 5.1.1.2. Increasing initiatives for the awareness regarding liver cancer
      • 5.1.1.3. Rapid adoption of precision medicine and emergence of targeted therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost for developing liver cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing regulatory approvals for the liver cancer drugs
      • 5.1.3.2. Growing R&D investments for the development of novel drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse side effects of liver cancer drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Liver Cancer Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Immuno Therapy
  • 6.3. Targeted Therapy

7. Liver Cancer Drugs Market, by Distribution channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Online Pharmacy
  • 7.4. Retail Pharmacy

8. Americas Liver Cancer Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Liver Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Liver Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Bristol-Myers Squibb Company
  • 6. Celsion Corporation
  • 7. Eisai Co., Ltd.
  • 8. Eli Lilly and Company
  • 9. Exelixis, Inc.
  • 10. F. Hoffmann-La Roche Ltd
  • 11. Lion TCR Pte. Ltd.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Ono Pharmaceutical Co., Ltd.
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. LIVER CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. LIVER CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LIVER CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LIVER CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNO THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023